Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Articaine Volume Comparison for IANB in Irreversible Pulpitis
NCT05840913Phase 2Completed
- Sponsor
- Armed Forces Institute of Dentistry
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of articaine in irreversible pulpitis (2 arms), sponsored by Armed Forces Institute of Dentistry. Primary endpoint: Anesthetic Success Rate (Pain Control). Started Dec 2023; status: completed.
02
Drugs
articaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT05840913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840913.